The profound influence of Human papillomavirus (HPV) on the epidemiological pattern and
clinical course of head and neck cancer (HNSCC) has led to a change in the traditional …

The epidermal growth factor receptor (EGFR) has evolved over years into a main molecular
target for the treatment of different cancer entities. In this regard, the anti-EGFR antibody …

PURPOSE: To compare concurrent cisplatin (CDDP) and radiation (RT) with cetuximab
(C225) and RT for locally advanced head-and-neck cancer (LAHNC). METHODS AND …

Background: Planned neck dissection (ND) after radical chemoradiotherapy (CRT) for
locally advanced nodal metastases in patients with head and neck squamous cell …

Purpose: The purpose of the present study was to evaluate the anti–epidermal growth factor
receptor (EGFR) monoclonal antibody (mAb), cetuximab,(IMC-C225) and the anti-EGFRvIII …

PURPOSE: To compare functional effects of combined irradiation and EGFR inhibition in
different HNSCC tumour models in vivo with the results of molecular evaluations, aiming to …

Radiotherapy plays a key role in the management of early stage and locally advanced head
and neck squamous-cell carcinomas (HNSCC) either alone or, more frequently combined …

Purpose This study describes the long-term survival and toxicity outcomes of a multicenter
randomized phase 2 trial comparing radiation therapy (RT) plus cisplatin (CDDP) or …

Background Photodynamic therapy (PDT) is a promising cancer treatment modality that
involves the interaction of the photosensitizer, molecular oxygen and light of specific …

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …